Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release


Targovax ASA
Posted on: 02 Nov 16

Oslo, 2 November 2016: Reference is made to the announcement made by Targovax ASA ("Targovax" or the "Company") earlier today regarding the appointment of Oystein Soug as the new CEO of the Company.

The Board of Directors has resolved to grant 150,000 share options in the Company under the Company's long term incentive program, each with a strike price of NOK 9.30, to Oystein Soug.

Further, the Board will, subject to the resolution by the general meeting of the Company to increase the option pool, at the time of such resolution grant to Oystein Soug the number share options required in order to bring his total holding of share options to 1.2% of the total number of outstanding shares, options and RSUs in Targovax at that time.

Following the grant of the 150,000 share options referred to above, Oystein Soug will own 100,000 shares and hold 540,000 options in the Company.

For further information, please contact:

Oystein Soug, CEO
Phone: +47 90 6565 25

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Targovax ASA via GlobeNewswire

Last updated on: 03/11/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.